Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CD20 Positive: early-phase trial registry
A small indexed set (6 trials) with no open enrollment listed right now.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · none currently recruiting · #2,866 of 28,707 conditions by registered trial count
CD20 Positive: 6 US clinical trials tracked, none currently recruiting.
CD20 Positive is the subject of 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition cd20-positive
OPEN 0 | RECR 0% | LATE 0 | EARLY 6 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
CD20 Positive has no open enrollment in this registry pull (6 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CD20 Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CD20 Positive is recruiting below its size-band peers.
0 of 6 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates CD20 Positive research.
M.D. Anderson Cancer Center accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most CD20 Positive trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
CD20 Positive research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
6 total, page 1 of 1
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT01880567
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
NCT03946878
Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
Roswell Park Cancer Institute
NCT01959698
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
NCT04007029
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
M.D. Anderson Cancer Center
NCT00880815
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
National Cancer Institute (NCI)
NCT02219737
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on CD20 Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CD20 Positive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CD20 Positive page
6 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No CD20 Positive trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- M.D. Anderson Cancer Center sponsors the most CD20 Positive trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CD20 Positive condition card totals 6 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.